IND SWIFT LA share price has zoomed 20% and is presently trading at Rs 166.4.
Meanwhile, the BSE HEALTHCARE index is at 40,597.4 (up 1.1%).
Among the top gainers in the BSE HEALTHCARE index today are SUVEN PHARMACEUTICALS (up 7.5%) and AJANTA PHARMA (up 7.3%).
POLY MEDICURE (down 4.3%) and NARAYANA HRUDAYALAYA (down 1.6%) are among the top losers today.
Over the last one year, IND SWIFT LA has moved up from Rs 97.1 to Rs 166.4, registering a gain of Rs 69.3 (up 71.3%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,736.5 to 40,597.4, registering a gain of 46.4% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 105.8%), Jubilant Pharmova (up 105.3%) and Cadila Healthcare (up 97.9%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,664.1 (up 0.3%).
The top gainers among the BSE Sensex today are Asian Paints (up 2.6%) and JSW Steel (up 2.4%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,934.3 (up 0.3%). HDFC LIFE INSURANCE and Asian Paints are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,527.7 to 81,664.1, registering a gain of 15,136.4 points (up 22.8%).
IND SWIFT LA net profit grew 1053.7% YoY to Rs 2,389 million for the quarter ended March 2024, compared to a loss of Rs 250 million a year ago. Net sales rose 29.3% to Rs 3,933 million during the period as against Rs 3,042 million in January-March 2023.
For the year ended March 2023, IND SWIFT LA reported 2325.7% increase in net profit to Rs 478 million compared to net loss of Rs 21 million during FY22. Revenue of the company grew 16.2% to Rs 12,073 million during FY23.
The current Price to earnings ratio of IND SWIFT LA, based on rolling 12 month earnings, stands at 3.2.
Equitymaster requests your view! Post a comment on "IND SWIFT LA Gains 20%; BSE HEALTHCARE Index Up 1.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!